Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline
- 9 December 2003
- journal article
- research article
- Published by Elsevier in Neuroscience Letters
- Vol. 355 (3) , 169-172
- https://doi.org/10.1016/j.neulet.2003.10.067
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitorNeuroscience Letters, 2003
- Neuroprotective agents for clinical trials in Parkinson’s diseaseNeurology, 2003
- Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: microdialysis study on dopamine release and free radical generationJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2003
- Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behavioursNeuropharmacology, 2002
- A Controlled Trial of Rasagiline in Early Parkinson DiseaseArchives of Neurology, 2002
- Mitochondrial permeability transition mediates apoptosis induced by N‐methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl‐2 and rasagiline, N‐propargyl‐1(R)‐aminoindanJournal of Neurochemistry, 2002
- Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cellsEuropean Journal of Pharmacology, 2001
- Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: time-course and mechanismsNeuropharmacology, 1999
- (–)‐Deprenyl alters the survival of adult murine facial motoneurons after axotomy: Increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutantsJournal of Neuroscience Research, 1994
- IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASEThe Lancet, 1977